🚀 VC round data is live in beta, check it out!
Largest Medical Devices Public Companies
Benchmark revenue and EBITDA valuation multiples for public comps like
Samsung, Johnson & Johnson, Roche, Siemens and Abbott.
 | $138 | +275% | $920B | $853B | 3.2x | 9.3x | ||
 | $240 | +53% | $577B | $605B | 6.3x | 17.0x | ||
 | $59 | +43% | $377B | $400B | 5.0x | 12.7x | ||
 | $261 | +12% | $204B | $249B | 2.7x | 14.8x | ||
| $114 | -13% | $198B | $203B | 4.5x | 16.8x | ||
| $509 | +19% | $191B | $220B | 4.9x | 19.5x | ||
| $496 | -4% | $176B | $170B | 16.3x | 37.7x | ||
| $387 | +4% | $148B | $160B | 6.2x | 21.7x | ||
| $206 | +3% | $146B | $161B | 6.5x | 20.6x | ||
| $98 | +16% | $126B | $146B | 4.0x | 14.3x | ||
| $76 | -26% | $113B | $123B | 5.9x | 19.0x | ||
| $48 | -13% | $53B | $51B | 1.9x | 9.3x | ||
| $637 | +47% | $51B | $51B | 11.7x | 33.4x | ||
| $87 | +15% | $51B | $47B | 7.6x | 25.1x | ||
| $85 | -12% | $41B | $45B | 4.3x | 16.9x | ||
| $25 | -5% | $37B | $36B | 6.5x | 16.9x | ||
| $79 | +12% | $36B | $42B | 2.0x | 11.3x | ||
| $118 | +10% | $33B | $35B | 4.9x | 16.9x | ||
 | $27 | -15% | $33B | $30B | 6.1x | 18.9x | ||
| $307 | -12% | $30B | $31B | 7.7x | 22.8x | ||
 | $30 | +18% | $29B | $35B | 1.6x | 9.9x | ||
| $74 | +3% | $28B | $28B | 5.8x | 19.6x | ||
| $1,325 | +24% | $27B | $29B | 7.1x | 22.8x | ||
| $248 | +10% | $24B | $26B | 4.4x | 15.5x | ||
 | $54 | +48% | $21B | $21B | 6.3x | 25.2x | ||
| $133 | +71% | $20B | $21B | 4.8x | 17.1x | ||
| $207 | -13% | $20B | $23B | 6.4x | 20.7x | ||
| $99 | -3% | $19B | $26B | 3.2x | 9.6x | ||
 | $8 | -33% | $17B | $21B | 4.8x | 14.9x | ||
| $243 | -4% | $17B | $17B | 6.0x | 25.5x | ||
| $75 | +30% | $17B | $17B | 4.1x | 12.5x | ||
| $82 | +0% | $16B | $18B | 4.4x | 13.9x | ||
| $18 | -5% | $15B | $14B | 7.0x | 42.1x | ||
| $17 | +23% | $15B | $17B | 2.8x | 10.7x | ||
| $239 | -26% | $14B | $14B | 3.0x | 11.7x | ||
 | $23 | +18% | $14B | $14B | 10.4x | 30.7x | ||
| $189 | +9% | $14B | $13B | 3.1x | 11.4x | ||
| $342 | +17% | $13B | $13B | 9.1x | 47.1x | ||
| $457 | +48% | $13B | $13B | 4.8x | 22.0x | ||
| $46 | -11% | $13B | $23B | 1.0x | 5.5x | ||
| $73 | +10% | $13B | $16B | 2.0x | 7.3x | ||
| $94 | +31% | $13B | $12B | 4.1x | 12.9x | ||
| $20 | -37% | $10B | $18B | 1.6x | 8.2x | ||
 | $9 | -22% | $10B | $10B | 1.6x | 10.3x | ||
 | $10 | +3% | $10B | $10B | 3.6x | 13.4x | ||
| $175 | +9% | $9B | $9B | 6.1x | 20.6x | ||
 | $135 | -31% | $9B | $9B | 5.4x | 20.5x | ||
| $26 | +14% | $8B | $7B | 1.9x | 11.6x | ||
| $278 | +15% | $7B | $7B | 2.8x | 16.0x | ||
| $121 | +29% | $7B | $7B | 12.8x | (350.5x) | ||
 | $18 | +66% | $6B | $11B | 2.2x | 12.2x | ||
| $30 | -18% | $6B | $9B | 2.5x | 10.7x | ||
| $21 | -16% | $6B | $6B | 16.1x | 26.9x | ||
| $3 | -6% | $6B | $8B | 3.1x | 11.8x | ||
| $285 | -12% | $6B | $6B | 7.8x | 28.4x | ||
| $8 | -1% | $6B | $6B | 8.0x | 18.5x | ||
| $38 | -4% | $6B | $7B | 2.1x | 13.0x | ||
| $21 | -- | $6B | $6B | 6.4x | 38.0x | ||
| $9 | -45% | $6B | $6B | 1.8x | 8.3x | ||
 | $21 | +4% | $6B | $6B | 1.7x | 9.0x | ||
| $23 | +41% | $6B | $6B | 6.5x | 26.2x | ||
| $6 | +10% | $6B | $4B | 3.5x | 17.5x | ||
| $131 | +114% | $6B | $5B | 2.2x | 11.1x | ||
| $123 | -10% | $5B | $8B | 3.8x | 13.3x | ||
| $20 | +46% | $5B | $5B | 5.9x | 16.7x | ||
| $147 | +60% | $5B | $5B | 7.9x | 31.7x | ||
| $141 | +18% | $5B | $5B | 4.9x | 21.6x | ||
| $29 | +83% | $5B | $5B | 1.9x | 13.7x | ||
| $34 | -19% | $5B | $5B | 11.4x | 28.7x | ||
| $3 | +58% | $5B | $5B | 5.0x | 17.1x | ||
| $44 | +37% | $5B | $4B | 0.8x | — | ||
| $344 | -23% | $5B | $5B | 5.5x | 12.0x | ||
| $77 | -19% | $5B | $5B | 3.2x | 12.8x | ||
| $65 | -- | $4B | $5B | 2.8x | 11.4x | ||
| $128 | +20% | $4B | $4B | 5.5x | 55.0x | ||
| $14 | -- | $4B | $4B | — | — | ||
| $55 | +85% | $4B | $4B | 3.8x | 17.4x | ||
| $200 | +18% | $4B | $4B | 4.9x | 17.8x | ||
| $9 | -18% | $4B | $4B | 8.4x | 97.5x | ||
| $20 | -36% | $4B | $4B | 11.2x | 44.1x | ||
| $70 | +90% | $4B | $4B | 2.6x | 11.3x | ||
| $13 | +56% | $4B | $4B | 2.7x | 14.3x | ||
| $81 | -- | $4B | $4B | 10.6x | 89.1x | ||
| $142 | +4% | $4B | $5B | 2.1x | 11.1x | ||
 | $15 | -23% | $3B | $5B | 1.9x | 8.2x | ||
| $12 | -33% | $3B | $3B | 3.3x | 17.7x | ||
| $5 | -6% | $3B | $3B | 4.6x | 12.3x | ||
| $86 | -32% | $3B | $4B | 2.3x | 10.6x | ||
| $64 | +1% | $3B | $4B | 2.9x | 9.2x | ||
| $5 | +106% | $3B | $3B | 9.9x | 41.6x | ||
| $7 | +29% | $3B | $3B | 6.8x | — | ||
| $6 | +9% | $3B | $2B | — | — | ||
| $30 | -57% | $3B | $3B | 1.0x | 6.6x | ||
| $1 | +52% | $3B | $3B | 3.0x | 25.5x | ||
| $106 | +17% | $2B | $2B | 8.7x | 28.8x | ||
| $6 | -- | $2B | $2B | — | — | ||
| $10 | +88% | $2B | $3B | 4.2x | 17.7x | ||
 | $15 | -- | $2B | $2B | — | — | ||
| $6 | +14% | $2B | $3B | 1.6x | 9.6x | ||
| $3 | -7% | $2B | $2B | 6.7x | 17.5x |
Financial data powered by FactSet and Morningstar. Valuation multiples as of last 12 months. For more data, start your free trial here.
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.